Welcome to our dedicated page for Heron Therapeutics SEC filings (Ticker: HRTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Heron Therapeutics, Inc. filings document financial results, governance matters, executive compensation arrangements, and capital-structure actions for a commercial-stage biotechnology company. Recent Form 8-K reports furnish quarterly and annual operating results, preliminary revenue disclosures, business updates for the Acute Care franchise, and material corporate events.
Proxy and governance filings cover director elections, board committee matters, executive pay, equity-award disclosure, and stockholder voting. Other filings record amendments to employment and change-in-control provisions, board appointments, and stockholder approvals tied to potential common-stock issuance from convertible senior unsecured promissory notes and Series A Convertible Preferred Stock.
Heron Therapeutics, Inc. amendment to a Schedule 13G/A reports that Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, filed as Reporting Persons and state 0% beneficial ownership of Heron common stock as of 03/31/2026. The filing lists addresses for the Reporting Persons and is signed on 05/13/2026. The cover-page rows referenced show zero shares and zero voting or dispositive power for each Reporting Person.
Heron Therapeutics, Inc. reported net product sales of $34.7M for the quarter ended March 31, 2026, down from $38.9M a year earlier, driven by weaker oncology sales partly offset by growth in acute care products ZYNRELEF and APONVIE.
The company posted a net loss of $8.1M versus net income of $2.6M in the prior-year quarter, as gross margin declined to 69.4% and interest expense increased following 2025 debt refinancing. CINVANTI and SUSTOL sales fell, while ZYNRELEF and APONVIE gained share.
Heron ended the quarter with $44.8M in cash, cash equivalents and short-term investments and expects this liquidity to cover anticipated needs for at least one year based on its current operating plan, though management notes this depends on assumptions that could change.
Heron Therapeutics reported Q1 2026 total net revenue of $34.7 million, down 10.8% year-over-year, and posted a net loss of $8.1 million versus net income a year earlier. Adjusted EBITDA was a loss of $0.7 million, compared with a positive $6.2 million in Q1 2025.
The Acute Care franchise remained a growth driver, with net revenue up 32% to $13.6 million, including ZYNRELEF at $10.2 million and APONVIE at $3.4 million. Oncology Supportive Care net revenue declined to $21.1 million, reflecting lower CINVANTI and planned SUSTOL wind-down. The company ended the quarter with $44.8 million in cash, cash equivalents and short-term investments and reaffirmed 2026 guidance of $173–$183 million in net revenue and $10–$20 million in Adjusted EBITDA.
Heron Therapeutics Chief Operating Officer Mark Earl Hensley exercised equity awards and increased his direct share holdings. On May 6, 2026, he exercised derivative securities to acquire 125,000 shares of common stock, reflecting the settlement of restricted stock units as equity compensation rather than a cash purchase.
Following the transaction, he directly holds 136,770 shares of common stock and 375,000 restricted stock units. Each restricted stock unit represents a contingent right to receive one share of common stock and vests 25% on the first anniversary of the grant date of May 6, 2025, then in twelve equal quarterly installments thereafter.
Heron Therapeutics Chief Operating Officer Mark Earl Hensley reported an automatic RSU conversion into common stock. On April 30, 2026, 11,770 restricted stock units converted into 11,770 shares of common stock at a stated price of $0.00 per share, leaving him with 11,770 common shares directly held.
The derivative section shows 11,770 RSUs converted into common stock and 176,545 restricted stock units remaining after the transaction. A prior grant on January 30, 2026 awarded 188,315 RSUs, scheduled to vest in 16 equal quarterly installments beginning one quarter after the grant date.
Heron Therapeutics EVP and Chief Development Officer William P. Forbes exercised restricted stock units into common shares. On April 30, 2026, he exercised awards covering 23,464 shares of common stock in two transactions. Following these exercises, he directly holds 209,111 shares of common stock and 128,638 restricted stock units, which each represent a contingent right to receive one share of common stock. The RSUs vest in 16 equal quarterly installments under time-based schedules beginning one quarter after their respective grant dates.
Heron Therapeutics EVP and CFO Ira Duarte exercised restricted stock units into common shares in a compensation-related transaction. On April 30, 2026, Duarte converted 13,535 and 11,694 restricted stock units into the same number of Heron Therapeutics common shares, with no open-market sales reported. Footnotes explain each restricted stock unit represents a right to receive one common share and that 216,562 RSUs granted in January 2026 vest in 16 equal quarterly installments, highlighting an ongoing, time-based equity compensation program.
Heron Therapeutics Chief Executive Officer Craig A. Collard exercised restricted stock units into common stock in a compensation-related transaction. He acquired 50,021 shares and 34,789 shares of common stock upon conversion of RSUs, reflecting previously granted equity awards that vest over time rather than open-market purchases or sales. Collard’s RSU program includes a grant of 800,337 units that vest in 16 equal quarterly installments beginning after the January 30, 2026 date of grant. Footnotes also note 11,023 shares acquired under the company’s Employee Stock Purchase Plan on April 30, 2026.
Heron Therapeutics, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on June 11, 2026. Stockholders will elect seven directors, ratify Withum Smith+Brown as auditor, and cast an advisory vote on 2025 executive pay.
The company is also seeking approval to amend and restate its 2007 Equity Incentive Plan to add 16,560,000 additional shares and to amend its Employee Stock Purchase Plan to add 10,000,000 shares, expanding equity available for employees and directors. Another advisory proposal asks stockholders to ratify the company’s Tax Benefits Preservation Plan.
The proxy describes Heron’s board structure, committee memberships, governance policies, and key shareholders. As of April 14, 2026, there were 188,638,866 common shares outstanding. It also details a 2025 private placement and a $35.0 million senior unsecured convertible note issuance with major existing investors.